Photo of Shiow-Lin Pan

View Scopus Profile

Shiow-Lin Pan

Professor

 https://orcid.org/0000-0001-7449-3539
  • 3052 Citations
  • 34 h-Index
19962020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Education

  • 2002 Ph.D. National Taiwan University
  • 1994 M.S. Taipei Medical University

Experience

  • 2019- Director, Ph.D Program in Biotechnology Research and Development, Taipei Medical University
  • 2018- Professor, Master Program in Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University
  • 2016-2018 Professor, Ph.D. Program for Cancer Molecular Biology and Drug Discovery, Taipei Medical University
  • 2013-2016 Associate Professor, Ph.D. Program for Cancer Molecular Biology and Drug Discovery, Taipei Medical University
  • 2008-2013 Assistant Professor, Department of Pharmacology, Taipei Medical University
  • 2009-2013 Assistant Investigator, National Health Research Institutes
  • 2007-2009 Assistant Investigator, National Taiwan University
  • 2002-2007 Postdoctor, National Taiwan Universiy
  • 1994-1998 Teaching Assistant, Chang-Gung University

Research Interests

  • Drug Discovery
  • Disease animal model
  • Pharmacology

URL

Awards

  • 2019 Single Research Project Budget Award, Taipei Medical University

Fingerprint Dive into the research topics where Shiow-Lin Pan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 9 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

新穎性選擇性HDAC抑制劑之抗癌藥物開發與藥理機轉探討(2/3)

Pan, S.

8/1/19 → 7/31/20

Project: A - Government Institution › b - Ministry of Science and Technology

選擇性抗癌標靶藥物HDAC6抑制劑臨床前試驗研究(II)

Pan, S.

5/1/19 → 10/1/19

Project: A - Government Institution › b - Ministry of Science and Technology

新穎性選擇性HDAC抑制劑之抗癌藥物開發與藥理機轉探討(1/3)

Pan, S.

8/1/18 → 7/1/19

Project: A - Government Institution › b - Ministry of Science and Technology

選擇性抗癌標靶藥物HDAC6抑制劑臨床前試驗研究

Pan, S.

12/1/17 → 10/31/18

Project: A - Government Institution › b - Ministry of Science and Technology

選擇性HDAC1及2抑制劑作為新穎性抗癌藥物之藥物開發與藥理機轉探討

Pan, S.

8/1/17 → 7/31/18

Project: A - Government Institution › b - Ministry of Science and Technology

Research Output

  • 3052 Citations
  • 34 h-Index
  • 131 Article
  • 1 Comment/debate

Corrigendum to: TW-01, a piperazinedione-derived compound, inhibits Ras-mediated cell proliferation and angioplasty-induced vascular restenosis “Toxicol Appl Pharmacol. 2016;305:194–202” (Toxicology and Applied Pharmacology (2016) 305 (194–202)(S0041008X16301478)(10.1016/j.taap.2016.06.013))

Lin, C. F., Huang, H. L., Peng, C. Y., Lee, Y. C., Wang, H. P., Teng, C. M. & Pan, S. L., Jan 15 2020, In : Toxicology and Applied Pharmacology. 387, 114858.

Research output: Contribution to journal › Comment/debate

Open Access

    • Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo

    Ojha, R., Nepali, K., Chen, C. H., Chuang, K. H., Wu, T. Y., Lin, T. E., Hsu, K. C., Chao, M. W., Lai, M. J., Lin, M. H., Huang, H. L., Chang, C. D., Pan, S. L., Chen, M. C. & Liou, J. P., Mar 15 2020, In : European Journal of Medicinal Chemistry. 190, 112086.

    Research output: Contribution to journal › Article

    • N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression

    Mehndiratta, S., Lin, M. H., Wu, Y. W., Chen, C. H., Wu, T. Y., Chuang, K. H., Chao, M. W., Chen, Y. Y., Pan, S. L., Chen, M. C. & Liou, J. P., Jan 1 2020, In : European Journal of Medicinal Chemistry. 185, p. 111725 111725.

    Research output: Contribution to journal › Article

    • 1 Citation (Scopus)

    Amide-tethered quinoline-resorcinol conjugates as a new class of HSP90 inhibitors suppressing the growth of prostate cancer cells

    Nepali, K., Lin, M. H., Chao, M. W., Peng, S. J., Hsu, K. C., Eight Lin, T., Chen, M. C., Lai, M. J., Pan, S. L. & Liou, J. P., Oct 1 2019, In : Bioorganic Chemistry. 91, 103119.

    Research output: Contribution to journal › Article

    • 1 Citation (Scopus)

    Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo

    Hsieh, Y. L., Tu, H. J., Pan, S. L., Liou, J. P. & Yang, C. R., Jun 1 2019, In : Biochimica et Biophysica Acta - Molecular Cell Research. 1866, 6, p. 992-1003 12 p.

    Research output: Contribution to journal › Article

    • 5 Citations (Scopus)